CANNASSURE THERAPEUTICS LTD

Altre lingue Cannassure Therapeutics Ltd

Azioni

CSURE-M

IL0001110134

Tempo differito TEL AVIV STOCK EXCHANGE Altri mercati azionari 13:24:10 25/04/2024			Variaz. 5gg	Var. 1 gen.
1.326 ^ILa	+10,04%		+18,39%	+174,53%

27/03	Cannassure Therapeutics Ltd riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
2023	Cannassure Therapeutics Ltd riporta i risultati degli utili per il semestre conclusosi il 30 giugno 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Cannassure Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Cannassure Therapeutics Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	31/08/23
Cannassure Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	26/03/23
Cannassure Was Granted A Patent for an Oral Delivery Method of Cannabis and Cannabinoids Compositions by the Israel Patents Authority	09/08/21
DanCann Pharma A/S : publishes Year-end report for 2020	26/02/21
Cannassure Therapeutics : DanCann Pharma's strategic partner, Cannassure Therapeutics Ltd., enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO® technology	18/01/21
Lipidor : and Cannassure enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO technology	18/01/21
DanCann Pharma A/S : enter exclusive agreement with Cannassure Therapeutics to be multinational distributor for Scandinavia (Denmark, Norway, Sweden, and Finland)	15/12/20
Lipidor : publishes interim report for Q3 2020	19/11/20
Lipidor : announces positive outcome of feasibility study for development of topical medical cannabis products based on the company's AKVANO® technology	30/09/20
Cannassure Therapeutics : Ltd and Lipidor AB Enter a Feasibility Study and Licence Option Agreement for Development and Sales of Topical Medical Cannabis Products Based on AKVANO Technology	11/12/19
Lipidor (Nasdaq First North: LIPI) and Cannassure (TASE:CSURE) enter a feasibility study and licence option agreement for development and sales of topical medical cannabis products	10/12/19

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Come gli esperti, accedi a tutti i resoconti e scova prima di tutti le migliori opportunità.

fermer